| abstract |
The present disclosure relates to the generation and use of an improved set of biomarkers that are aryl hydrocarbon receptor (AHR) target genes referred to as “AHR biomarkers”. The AHR biomarkers described herein allow for efficient determination of AHR activation groups and sub-groups, particularly for improved classification of tumors. As used herein, the AHR activation group is referred to as an “AHR activation signature”. AHR biomarkers include, for example, markers important for diagnosis and therapy for selecting patients for treatment with AHR activation modulating interventions, and for monitoring therapy response. |